BIOMARIN PHARMACEUTICAL ($BMRN) posted quarterly earnings results on Monday, October 27th. The company reported earnings of $0.12 per share, missing estimates of $0.47 by $0.35. The company also reported revenue of $776,130,000, missing estimates of $799,199,070 by $-23,069,070.
You can see Quiver Quantitative's $BMRN stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
BIOMARIN PHARMACEUTICAL Insider Trading Activity
BIOMARIN PHARMACEUTICAL insiders have traded $BMRN stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $BMRN stock by insiders over the last 6 months:
- ERIN BURKHART (GVP, Chief Accounting Officer) sold 1,786 shares for an estimated $105,927
- CRISTIN HUBBARD (EVP, Chief Commercial Officer) sold 273 shares for an estimated $17,723
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
BIOMARIN PHARMACEUTICAL Hedge Fund Activity
We have seen 324 institutional investors add shares of BIOMARIN PHARMACEUTICAL stock to their portfolio, and 266 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL RESEARCH GLOBAL INVESTORS removed 8,758,776 shares (-95.7%) from their portfolio in Q2 2025, for an estimated $481,469,916
- ELLIOTT INVESTMENT MANAGEMENT L.P. removed 3,500,338 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $192,413,579
- AQR CAPITAL MANAGEMENT LLC added 2,654,768 shares (+90.7%) to their portfolio in Q2 2025, for an estimated $145,932,596
- MILLENNIUM MANAGEMENT LLC added 2,159,083 shares (+319.7%) to their portfolio in Q2 2025, for an estimated $118,684,792
- AMERIPRISE FINANCIAL INC removed 2,046,391 shares (-48.6%) from their portfolio in Q2 2025, for an estimated $112,490,113
- PRIMECAP MANAGEMENT CO/CA/ removed 2,001,108 shares (-11.3%) from their portfolio in Q2 2025, for an estimated $110,000,906
- NUVEEN, LLC removed 1,872,754 shares (-71.8%) from their portfolio in Q2 2025, for an estimated $102,945,287
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
BIOMARIN PHARMACEUTICAL Analyst Ratings
Wall Street analysts have issued reports on $BMRN in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Guggenheim issued a "Buy" rating on 08/06/2025
- UBS issued a "Buy" rating on 08/05/2025
- Goldman Sachs issued a "Buy" rating on 05/05/2025
To track analyst ratings and price targets for BIOMARIN PHARMACEUTICAL, check out Quiver Quantitative's $BMRN forecast page.
BIOMARIN PHARMACEUTICAL Price Targets
Multiple analysts have issued price targets for $BMRN recently. We have seen 7 analysts offer price targets for $BMRN in the last 6 months, with a median target of $104.0.
Here are some recent targets:
- Jessica Fye from JP Morgan set a target price of $119.0 on 10/09/2025
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $60.0 on 09/08/2025
- Debjit Chattopadhyay from Guggenheim set a target price of $106.0 on 08/06/2025
- Eliana Merle from UBS set a target price of $114.0 on 08/05/2025
- Matthew Harrison from Morgan Stanley set a target price of $96.0 on 07/22/2025
- Salveen Richter from Goldman Sachs set a target price of $104.0 on 05/05/2025
- David Lebovitz from Citigroup set a target price of $78.0 on 05/02/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
